Faster Cardiac Answers with HighSensitivity Troponin [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high- sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-41409 QUIDELORTHO CORPORATION (Exact name of registrant as specified in its charter) De ...

QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference.The Company's presentation is scheduled for Tuesday, March 3, 2026, at 1:40 p.m. ET ...

Key Takeaways QDEL signed a long-term supply pact with Lifotronic to expand its global immunoassay portfolio.Deal adds 25 new assays and access to 70-test menu across low- to high-throughput platforms.QuidelOrtho reported Q4 2025 revenues of $723.6M, up 2.2%, with EPS of 46 cents.QuidelOrtho (QDEL) recently entered a long-term strategic supply agreement with Lifotronic Technology to expand its global immunoassay portfolio across select international markets. The deal gives the company access to multiple ana ...

Core Insights - QuidelOrtho Corporation (QDEL) reported adjusted earnings per share (EPS) of 46 cents for Q4 2025, a decrease from 63 cents year-over-year, but exceeded the Zacks Consensus Estimate by 6.9% [1] - The company registered revenues of $723.6 million in Q4 2025, reflecting a 2.2% year-over-year increase and surpassing the Zacks Consensus Estimate by 3.6% [2] Financial Performance - The GAAP loss per share for Q4 was $1.92, an improvement from a loss of $2.65 in the same quarter last year [1] - Adjusted gross profit declined 1.8% year-over-year to $325.2 million, with an adjusted gross margin contracting by 190 basis points to 44.9% [9] - Adjusted operating profit totaled $89.3 million, down 8.7% from the prior-year quarter, with an adjusted operating margin of 12.3%, a contraction of 150 basis points [10] Revenue Breakdown - Respiratory revenues were $123.3 million, down 13.9% year-over-year, while Non-Respiratory revenues increased to $600.3 million, up 6.3% [2] - Labs revenues reached $389.2 million, an 8.1% increase, while Immunohematology revenues were $141 million, up 3.4% [3][4] - Donor Screening revenues fell significantly to $11.8 million, down 40.1%, and Point of Care revenues declined to $173.1 million, down 6.4% [4] Geographical Performance - North America revenues were $390.1 million, reflecting a decline of 2.4%, while EMEA revenues increased by 9.3% to $92.7 million [6] - Revenues from China amounted to $91.7 million, up 5.5%, and Latin America revenues increased by 22% to $73.2 million [8] Future Guidance - For 2026, QuidelOrtho expects total revenues to be in the range of $2.7 billion to $2.9 billion, with a consensus estimate of $2.71 billion [12] - The company anticipates steady growth in its core Labs business and low-single-digit growth in Immunohematology, while Point-of-Care revenues are expected to remain flat [13][14]

Core Insights - QuidelOrtho reported $2.73 billion in revenue for the full year, with non-respiratory revenue growing 5% and Labs business growing 6%, representing 55% of total revenue [1][6] - The company experienced a decline in respiratory revenue, totaling $402 million, primarily due to lower COVID testing [1][6] Financial Performance - For Q4, QuidelOrtho reported revenue of $724 million, a 2% year-over-year increase; excluding COVID and donor screening, revenue growth was 7% [2] - The company achieved $140 million in cost savings, expanded adjusted EBITDA margins to the low 20% range, and reported an adjusted EBITDA margin of 22% for 2025, a 240 basis point improvement year-over-year [3][6] - Adjusted diluted EPS was $0.46 in Q4 and $2.12 for the full year, representing a 15% growth year-over-year [6] Segment and Regional Performance - Labs revenue grew 7% in Q4 and 6% for the full year, driven by strength in clinical chemistry; respiratory revenue declined 14% in Q4 and 20% for the year [8][9] - North America revenue was up 4% in Q4 but down 2% for the year; Europe, Middle East, and Africa was flat in Q4 and up 4% for the year [9] Research and Development - Recent FDA clearances include a high-sensitivity Troponin I assay and a DAT direct anticoagulant test card; plans for the launch of the VITROS 450 platform are underway [5][10] - The Lex molecular platform is in the final stages of FDA review, designed for point-of-care applications [13] 2026 Outlook - Management guided for 2026 revenue of $2.7 billion to $2.9 billion, with expected growth in Labs and Immunohematology, and a decline in molecular diagnostics due to the discontinuation of the Savanna business [17][18] - Adjusted EBITDA is expected to be between $630 million and $670 million, implying an adjusted EBITDA margin of about 23.3% [19] Leadership Update - The CFO, Joe Busky, will retire in June, and the company has initiated a search for a successor [20]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $724 million, representing a 2% year-over-year increase, with a 7% growth in non-respiratory revenue excluding donor screening [7][18] - Full year revenue reached $2.73 billion, achieving the company's financial guidance for 2025, with non-respiratory revenue growing 5% [7][18] - Adjusted EBITDA margin was 22%, reflecting a 240 basis point improvement over the prior year [8][22] - Adjusted diluted EPS was $0.46 in Q4 and $2.12 for the full year, indicating a 15% year-over-year growth [22] Business Line Data and Key Metrics Changes - Labs business reported a strong growth of 7% in Q4 and 6% for the full year, accounting for 55% of total company revenue [7][18] - Immunohematology business grew 3% for the full year, maintaining its leading global market position [18] - Triage business saw a revenue increase of 16% in Q4 and 7% for the full year [18] - Respiratory revenue declined 14% in Q4 and 20% for the full year due to lower COVID testing [18] Market Data and Key Metrics Changes - North America region revenue was up 4% in Q4 but down 2% for the year, excluding donor screening [20] - Europe, Middle East, and Africa showed flat growth for the quarter and 4% growth for the year, with a significant increase in Adjusted EBITDA margins by over 900 basis points [20] - Latin America experienced a 17% increase in Q4 and 18% for the year, while Japan and Asia-Pacific grew 4% in Q4 and 6% for the year [20] - China grew 5% in Q4 and 3% for the full year [21] Company Strategy and Development Direction - The company established three priorities: customer-centric operations, strengthening operational and financial performance, and accelerating product development for long-term growth [6] - The focus is on optimizing the customer experience and driving effective execution across all business dimensions [9] - The company aims to maximize value by delivering superior outcomes for customers and converting that value into attractive returns for shareholders [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth, citing strong market positions and high renewal rates [35] - The company anticipates continued growth in the Labs business and is optimistic about new product launches in 2026 [14][25] - Management acknowledged challenges in cash flow conversion but emphasized ongoing efforts to improve cash flow metrics [31][88] Other Important Information - A significant non-cash goodwill impairment charge of $701 million was recorded in Q3, which does not impact cash or operations [8][22] - Joe Busky, CFO, announced his retirement effective June 2026, with a search for his successor already initiated [9][10] Q&A Session Summary Question: Free cash flow guidance and timing issues - Joe Busky explained that Q4 cash flow was lower than expected due to timing issues with accounts receivable and late revenue collection [30][31] Question: Sustainability of lab growth trends - Brian Blaser highlighted strong underlying growth rates across the business and emphasized opportunities in immunoassay and low market penetration [33][35] Question: China market updates - Management provided updates on potential nationalized value-based procurement programs but noted no new developments [40][41] Question: Gross margin performance - Joe Busky discussed factors affecting gross margins, including tariffs and product mix, and projected flat margins for 2026 [67][68] Question: Lex Diagnostics platform timeline - Jonathan Siegrist confirmed that the FDA review process for the Lex platform is progressing as planned, with no current issues [72] Question: R&D pipeline and product launches - Management indicated a focus on expanding the product portfolio and enhancing offerings in both domestic and international markets [76][78]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $724 million, representing a 2% year-over-year increase from $708 million, with a 7% growth in non-respiratory revenue excluding donor screening [7][18] - Full year revenue reached $2.73 billion, achieving the 2025 financial guidance, with non-respiratory revenue growing 5% [7][18] - Adjusted EBITDA margin was 22%, a 240 basis point improvement over the prior year [8][22] - Adjusted diluted EPS was $0.46 for Q4 and $2.12 for the full year, reflecting a 15% year-over-year growth [22] Business Line Data and Key Metrics Changes - Labs business reported a 7% growth in Q4 and 6% for the full year, representing 55% of total company revenue [7][18] - Immunohematology grew 3% for the full year, maintaining its leading global market position [18] - Triage business revenue increased by 16% in Q4 and 7% for the full year [18] - Respiratory revenue declined by 14% in Q4 and 20% for the full year due to lower COVID testing [18] Market Data and Key Metrics Changes - North America region revenue was up 4% in Q4 but down 2% for the year, excluding donor screening [20] - Europe, Middle East, and Africa (EMEA) growth was flat in Q4 and up 4% for the year, with adjusted EBITDA margins increasing by over 900 basis points [20] - Latin America saw a 17% increase in Q4 and 18% for the year, while Japan and Asia-Pacific grew 4% in Q4 and 6% for the year [20] - China grew 5% in Q4 and 3% for the full year [21] Company Strategy and Development Direction - The company established three priorities: customer-centric operations, strengthening operational and financial performance, and accelerating product development for long-term growth [6][9] - The focus is on optimizing the customer experience and driving effective execution across all business dimensions [9] - The company aims to maximize value by delivering superior outcomes for customers and converting that value into attractive returns for shareholders [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth, citing strong market positions and high renewal rates [35] - The company anticipates continued growth in the Labs business and is optimistic about new product launches in 2026 [14][25] - Management acknowledged challenges in cash flow conversion but emphasized ongoing efforts to improve cash flow metrics [31][89] Other Important Information - A significant non-cash goodwill impairment charge of $701 million was recorded in Q3, which does not impact cash or operations [22] - The CFO announced plans to retire in June, with a search for a successor already initiated [9][10] Q&A Session Summary Question: Free cash flow guidance and timing issues - The CFO explained that Q4 cash flow was lower than expected due to timing issues with accounts receivable and late revenue collection [30][31] Question: Sustainability of Labs business growth - Management highlighted strong underlying growth rates and opportunities in immunoassay and underpenetrated markets as key factors for sustaining growth [35] Question: Updates on China market and VBP program - Management stated that there are no new updates on the nationalized VBP program for dry chemistry test strips, with potential impacts estimated at 0.5% to 1% of total revenue [40][41] Question: Gross margin outlook - The CFO discussed factors affecting gross margins, including tariffs and product mix, and projected flat gross margins for 2026 with potential improvements in the following years [68][70] Question: LEX Diagnostics platform timeline - Management indicated that the FDA review process for the LEX platform is progressing as planned, with no current issues [73] Question: R&D pipeline and U.S. market focus - Management confirmed that while OUS markets are a priority, there are plans to enhance the U.S. product offerings through new menu additions [77][79]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $724 million, a 2% increase from $708 million in the prior year, with a 7% growth in non-respiratory revenue excluding donor screening [6][18] - Full year revenue reached $2.73 billion, achieving the 2025 financial guidance, with non-respiratory revenue growing 5% [6][18] - Adjusted EBITDA margin was 22%, reflecting a 240 basis point improvement year-over-year [8][21] - Adjusted diluted EPS was $0.46 for Q4 and $2.12 for the full year, representing a 15% year-over-year growth [21] Business Line Data and Key Metrics Changes - Labs business reported a strong growth of 7% in Q4 and 6% for the full year, representing 55% of total company revenue [6][18] - Immunohematology grew 3% for the full year, maintaining its leading global market position [18] - Triage business revenue increased by 16% in Q4 and 7% for the full year [18] - Respiratory revenue declined by 14% in Q4 and 20% for the full year due to lower COVID testing [18] Market Data and Key Metrics Changes - North America region revenue was up 4% in Q4 but down 2% for the year, excluding donor screening [19] - Europe, Middle East, and Africa (EMEA) growth was flat for the quarter and up 4% for the year, with a significant increase in Adjusted EBITDA margins by over 900 basis points [19] - Latin America saw a 17% increase in Q4 and 18% for the year, while Japan and Asia-Pacific grew 4% in Q4 and 6% for the year [19] - China grew 5% in Q4 and 3% for the full year [19] Company Strategy and Development Direction - The company established three priorities: customer-centric operations, strengthening operational and financial performance, and accelerating product development for long-term growth [5] - The focus is on optimizing the customer experience and driving effective execution across all business dimensions [9] - The company aims to maximize value by delivering superior outcomes for customers and converting that value into attractive returns for shareholders [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth, citing strong market positions and high renewal rates [34] - The company anticipates continued growth in the Labs business and expects to launch new products in 2026, including the VITROS 450 platform [14][15] - Management acknowledged challenges in cash flow conversion but emphasized ongoing efforts to improve cash flow and margin performance [88] Other Important Information - A significant non-cash goodwill impairment charge of $701 million was recorded in Q3, which does not impact cash or operations [21] - The CFO announced plans to retire in June, with a search for a successor already initiated [9] Q&A Session Summary Question: Free cash flow guidance and timing of cash collections - Management explained that Q4 cash flow was lower than expected due to timing issues with cash collections, with $45 million expected to be collected in Q4 but realized in January [30][31] Question: Sustainability of lab growth trends - Management expressed optimism about sustaining growth, highlighting strong market positions and opportunities in immunoassay and low market penetration [34] Question: Updates on China and dry slide procurement - Management stated there were no new updates regarding the nationalized VBP program for dry chemistry test strips in China, with potential impacts estimated at 0.5% to 1% of total revenue [40] Question: Margins and direct procurement initiatives - Management indicated that direct procurement initiatives are expected to improve margins over time, with a goal of reaching closer to 50% gross margin in the coming years [68][69]

QuidelOrtho Fourth Quarter and Full-Year 2025 Financial Results February 11, 2026 QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 2 Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly his ...